103 results on '"Sacktor N"'
Search Results
2. A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa
- Author
-
Joska, J. A., Witten, J., Thomas, K. G., Robertson, C., Casson-Crook, M., Roosa, H., Creighton, J., Lyons, J., McArthur, J., and Sacktor, N. C.
- Published
- 2016
- Full Text
- View/download PDF
3. Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years
- Author
-
Tang, Bin, primary, Collier, A.C., additional, Morgello, S., additional, Cookson, D., additional, Sacktor, N., additional, Ellis, Ronald J., additional, Marra, Christina M., additional, Clifford, David B., additional, Gelman, Benjamin B., additional, Robinson-Papp, Jessica, additional, McCutchan, J. Allen, additional, Letendre, Scott, additional, Heaton, Robert K., additional, and Grant, Igor, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Association Between Lung and Cognitive Dysfunction in Men with Human Immunodeficiency Virus Infection
- Author
-
Hwang, Y.J., primary, Nouraie, S.M., additional, Becker, J.T., additional, Chang, D., additional, French, A.L., additional, Kunisaki, K.M., additional, Levine, A., additional, Martin, E., additional, McCormack, M.C., additional, Sacktor, N., additional, Weinstein, A., additional, and Morris, A.M., additional
- Published
- 2020
- Full Text
- View/download PDF
5. White matter damage, neuroinflammation, and neuronal integrity in HAND
- Author
-
Alakkas, A, Ellis, RJ, Watson, CW-M, Umlauf, A, Heaton, RK, Letendre, S, Collier, A, Marra, C, Clifford, DB, Gelman, B, Sacktor, N, Morgello, S, Simpson, D, McCutchan, JA, Kallianpur, A, Gianella, S, Marcotte, T, Grant, I, Fennema-Notestine, C, and CHARTER Group
- Subjects
CD4-Positive T-Lymphocytes ,Adult ,Male ,AIDS Dementia Complex ,Anti-HIV Agents ,Clinical Sciences ,Antiretroviral Therapy ,Neuroimaging ,Neuropsychological Tests ,HAND ,Severity of Illness Index ,Basal Ganglia ,Choline ,Memory ,Clinical Research ,Virology ,Acquired Cognitive Impairment ,Humans ,2.1 Biological and endogenous factors ,Highly Active ,Cognitive Dysfunction ,Longitudinal Studies ,Gray Matter ,Aetiology ,Aspartic Acid ,Neurosciences ,Organ Size ,Middle Aged ,Creatine ,Magnetic Resonance Imaging ,White Matter ,CD4 Lymphocyte Count ,Brain Disorders ,Infectious Diseases ,Mental Health ,Short-Term ,Hand Mri ,Medical Microbiology ,CHARTER Group ,Neurological ,Biomedical Imaging ,HIV/AIDS ,Female ,MRI - Abstract
HIV-associated neurocognitive disorders (HANDs) persist even with virologic suppression on combination antiretroviral therapy (cART), and the underlying pathophysiological mechanisms are not well understood. We performed structural magnetic resonance imaging and MR spectroscopy (MRS) in HIV+ individuals without major neurocognitive comorbidities. Study participants were classified as neurocognitively unimpaired (NU), asymptomatic (ANI), mild neurocognitive disorder (MND), or HIV-associated dementia (HAD). Using structural MRI, we measured volumes of cortical and subcortical gray matter and total and abnormal white matter (aWM). Using single-voxel MRS, we estimated metabolites in frontal gray matter (FGM) and frontal white matter (FWM) and basal ganglia (BG) regions. Adjusted odds ratios were used to compare HAND to NU. Among 253 participants, 40% met HAND criteria (21% ANI, 15% MND, and 4% HAD). Higher risk of HAND was associated with more aWM. Both HAD and MND also had smaller gray and white matter volumes than NU. Among individuals with undetectable plasma HIV RNA, structural volumetric findings were similar to the overall sample. MND had lower FWM creatine and higher FGM choline relative to NU, whereas HAD and ANI had lower BG N-acetyl aspartate relative to NU. In the virologically suppressed subgroup, however, ANI and MND had higher FGM choline compared to NU. Overall, HAND showed specific alterations (more aWM and inflammation; less gray matter volume and lower NAA). Some MR measures differentiated less severe subtypes of HAND from HAD. These MR alterations may represent legacy effects or accumulating changes, possibly related to medical comorbidities, antiretroviral therapy, or chronic effects of HIV brain infection.
- Published
- 2019
6. A-03 Ethnic/Racial Differences in Longitudinal Neurocognitive Change among People Living with HIV
- Author
-
Watson, C, primary, Kamalyan, L, additional, Hussain, M, additional, Tang, B, additional, Collier, A, additional, Clifford, D, additional, Gelman, B, additional, Sacktor, N, additional, Morgello, S, additional, McCutchan, J A, additional, Ellis, R, additional, Grant, I, additional, Heaton, R, additional, and Marquine, M, additional
- Published
- 2019
- Full Text
- View/download PDF
7. COMPARISON OF METRICS FOR THE IDENTIFICATION OF LONG-TERM DEPRESSION IN ABSENCE OF GOLD STANDARD
- Author
-
Armstrong, N, primary, Surkan, P J, additional, Treisman, G J, additional, Sacktor, N C, additional, Irwin, M R, additional, Stall, R C, additional, Jacobson, L P, additional, and Abraham, A G, additional
- Published
- 2018
- Full Text
- View/download PDF
8. 7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests
- Author
-
Mohamed, M., primary, Barker, P.B., additional, Skolasky, R.L., additional, and Sacktor, N., additional
- Published
- 2018
- Full Text
- View/download PDF
9. Prevalence of and risk factors for peripheral neuropathy in Rakai, Uganda
- Author
-
Saylor, D., primary, Nakigozi, G., additional, Nakasujja, N., additional, Kong, X., additional, Robertson, K., additional, Gray, R.H., additional, Wawer, M.J., additional, and Sacktor, N., additional
- Published
- 2015
- Full Text
- View/download PDF
10. Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus.
- Author
-
Ellis RJ, Sacktor N, Clifford DB, Marra CM, Collier AC, Gelman B, Robinson-Papp J, Letendre SL, and Heaton RK
- Subjects
- Cognition, Female, HIV, Humans, Male, Prospective Studies, HIV Infections complications, HIV Infections drug therapy, Neuralgia complications
- Abstract
Neuropathic pain and cognitive impairment are among the HIV-related conditions that have most stubbornly resisted amelioration by virally suppressive antiretroviral therapy. Overlaps between the regional brain substrates and mechanisms of neuropathic pain and cognitive disorders are increasingly recognized, yet no studies have examined the longitudinal relationship between these two disorders. Participants in the prospective, observational CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) cohort underwent standardized clinical evaluations for clinical examination findings of distal sensory polyneuropathy, reporting distal neuropathic pain and neurocognitive performance at study entry (baseline) and an average of 12 years later. Change in neuropathic pain and neuropathy status from baseline to follow-up was by self-report and repeat examination, and change in neurocognitive performance was assessed using a previously published summary regression-based change score. Relationships between incident or worsened neuropathic pain and neurocognitive change were evaluated using uni- and multivariable regressions, including age at baseline and other relevant covariates. Participants were 385 people with HIV, 91 (23.6%) females, mean ± standard deviation (SD) age at baseline 43.5 (7.81) years, ethnicity 44.9% African American, 10.6% Hispanic, 42.6% non-Hispanic white and 1.82% other. Baseline median (interquartile range) nadir CD4 was 175 (34 309) cells/µl and current CD4 was 454 (279 639). Incident or worsened distal neuropathic pain occurred in 98 (25.5%) over the follow-up period. People with HIV with incident or worsened distal neuropathic pain had significantly worsened neurocognitive performance at follow-up compared to those without incident or worsened distal neuropathic pain (summary regression-based change score mean ± SD -0.408 ± 0.700 versus -0.228 ± 0.613; P = 0.0158). This effect remained significant when considering viral suppression on antiretroviral therapy, incident diabetes and other covariates as predictors. Overall neurocognitive change related to neuropathic pain was driven primarily by changes in the domains of executive function and speed of information processing. Those with incident distal neuropathy signs did not have neurocognitive worsening, nor did individuals who used opioid analgesics or other pain-modulating drugs such as amitriptyline. Worsened neurocognitive performance in people with HIV was associated with worsened neuropathic pain but not with changes in physical signs of neuropathy, and this was not attributable to therapies for pain or depression or to differences in viral suppression. This finding implies that incident or worsened pain may signal increased risk for neurocognitive impairment, and deserves more investigation, particularly if better pain management might stabilize or improve neurocognitive performance., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
11. Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years.
- Author
-
Ellis RJ, Heaton RK, Tang B, Collier AC, Marra CM, Gelman BB, Morgello S, Clifford DB, Sacktor N, Cookson D, and Letendre S
- Abstract
Background: Neurocognitive (NC) impairment in people with HIV (PWH) is associated with important adverse outcomes, but no markers exist to predict long-term NC decline. We evaluated depressed mood and markers of persistent inflammation, oxidative stress and altered amyloid processing (all common in PWH) as predictors of NC worsening over 12 years., Methods: PWH were enrolled and followed longitudinally in the CNS HIV Antiretroviral Effects Research (CHARTER) study at six US sites. At entry we quantified biomarkers in blood of inflammation: (interleukin-6 [IL-6], C-reactive protein [CRP], monocyte chemoattractant protein type 1 [MCP-1], D-dimer, soluble sCD14 (sCD14), soluble tumor necrosis factor receptor - type II [sTNFR-II], neopterin, and soluble CD40 ligand [sCD40L], oxidative stress (protein carbonyls, 8-oxo-2'-deoxyguanosine [8-oxo-dG]) and altered amyloid processing [amyloid beta (Aβ)-42, soluble amyloid precursor protein-α (sAPPα)] using commercial immunoassays. The Beck Depression Inventory-II (BDI-II) assessed depressed mood at entry. NC decline over 12 years was evaluated using the published and validated summary (global) regression-based change score (sRBCS). A factor analysis reduced dimensionality of the biomarkers. Univariable and multiple regression models tested the relationship between baseline predictors and the outcome of neurocognitive decline., Results: Participants were 191 PWH, 37 (19.4%) women, 46.6% African American, 43.5% non-Hispanic white, 8.83% Hispanic, 15.7% white, 1.6% other; at study entry mean (SD) age 43.6 (8.06) years, estimated duration of HIV infection (median, IQR) 9.82 [4.44, 14.5] years, nadir CD4 104/μL (19,205), current CD4 568/μL (356, 817), and 80.1% had plasma HIV RNA <50 c/mL. Participants were enrolled between 2003 and 2007; median (IQR) duration of follow-up 12.4 [9.69, 16.2] years. Three biomarker factors were identified: Factor (F)1 (IL-6, CRP), F2 (sTNFR-II, neopterin) and F3 (sCD40L, sAPPα). Participants with higher F1, reflecting worse systemic inflammation at baseline, and higher F3, had greater decline in global neurocognition (r = -0.168, p = 0.0205 and r = -0.156, p = 0.0309, respectively). Of the F1 components, higher CRP levels were associated with worse decline (r = -0.154, p = 0.0332), while IL-6 did not (r = -0.109, p = 0.135). NC change was not significantly related to F2, nor to demographics, nadir and current CD4, viral suppression or baseline NC comorbidity ratings. Individuals with worse depressed mood at entry also experienced more NC decline (r = -0.1734, p = 0.0006). Together BDI-II (p = 0.0290), F1 (p = 0.0484) and F3 (p = 0.0309) contributed independently to NC decline (p = 0.0028); their interactions were not significant. Neither CRP nor IL-6 correlated significantly with depression., Conclusions: PWH with greater systemic inflammation and more depression at entry had greater NC decline over 12 years. Understanding the basis of this inflammatory state might be particularly important. These findings raise the possibility that targeted anti-inflammatory or antidepressant therapies may help prevent NC worsening in PWH with depression and inflammation., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
12. Baseline Neurocognitive Impairment (NCI) Is Associated With Incident Frailty but Baseline Frailty Does Not Predict Incident NCI in Older Persons With Human Immunodeficiency Virus (HIV).
- Author
-
Masters MC, Perez J, Wu K, Ellis RJ, Goodkin K, Koletar SL, Andrade A, Yang J, Brown TT, Palella FJ, Sacktor N, Tassiopoulos K, and Erlandson KM
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, HIV, Humans, Middle Aged, Odds Ratio, Frailty epidemiology, HIV Infections complications
- Abstract
Background: Neurocognitive impairment (NCI) and frailty are more prevalent among persons with human immunodeficiency virus (HIV, PWH) compared to those without HIV. Frailty and NCI often overlap with one another. Whether frailty precedes declines in neurocognitive function among PWH or vice versa has not been well established., Methods: AIDS Clinical Trials Group (ACTG) A5322 is an observational cohort study of older PWH. Participants undergo annual assessments for NCI and frailty. ACTG A5322 participants who developed NCI as indexed by tests of impaired executive functioning and processing speed during the first 3 years were compared to persons who maintained normal cognitive function; those who demonstrated resolution of NCI were compared to those who had persistent NCI. Participants were similarly compared by frailty trajectory. We fit multinomial logistic regression models to assess associations between baseline covariates (including NCI) and frailty, and associations between baseline covariates (including frailty) and NCI., Results: In total, 929 participants were included with a median age of 51 years (interquartile range [IQR] 46-56). At study entry, 16% had NCI, and 6% were frail. Over 3 years, 6% of participants developed NCI; 5% developed frailty. NCI was associated with development of frailty (odds ratio [OR] = 2.06; 95% confidence interval [CI] = .94, 4.48; P = .07). Further adjustment for confounding strengthened this association (OR = 2.79; 95% CI = 1.21, 6.43; P = .02). Baseline frailty however was not associated with NCI development., Conclusions: NCI was associated with increased risk of frailty, but frailty was not associated with development of NCI. These findings suggest that the presence of NCI in PWH should prompt monitoring for the development of frailty and interventions to prevent frailty in this population., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
13. Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy.
- Author
-
Diaz MM, Keltner JR, Simmons AN, Franklin D, Moore RC, Clifford D, Collier AC, Gelman BB, Marra PDC, McCutchan JA, Morgello S, Sacktor N, Best B, Notestine CF, Weibel SG, Grant I, Marcotte TD, Vaida F, Letendre S, Heaton R, and Ellis RJ
- Subjects
- Aged, Female, Humans, Longitudinal Studies, Middle Aged, Paresthesia epidemiology, Paresthesia etiology, Prospective Studies, Quality of Life, HIV Infections complications, HIV Infections drug therapy, Neuralgia epidemiology, Neuralgia etiology, Polyneuropathies diagnosis, Polyneuropathies epidemiology, Polyneuropathies etiology
- Abstract
Objective: Distal sensory polyneuropathy (DSP) is a disabling consequence of human immunodeficiency virus (HIV), leading to poor quality of life and more frequent falls in older age. Neuropathic pain and paresthesia are prevalent symptoms; however, there are currently no known curative treatments and the longitudinal course of pain in HIV-associated DSP is poorly characterized., Methods: This was a prospective longitudinal study of 265 people with HIV (PWH) enrolled in the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study with baseline and 12-year follow-up evaluations. Since pain and paresthesia are highly correlated, statistical decomposition was used to separate the two symptoms at baseline. Multivariable logistic regression analyses of decomposed variables were used to determine the effects of neuropathy symptoms at baseline on presence and worsening of distal neuropathic pain at 12-year follow-up, adjusted for covariates., Results: Mean age was 56 ± 8 years, and 21% were female at follow-up. Nearly the entire cohort (96%) was on antiretroviral therapy (ART), and 82% had suppressed (≤50 copies/mL) plasma viral loads at follow-up. Of those with pain at follow-up (n = 100), 23% had paresthesia at the initial visit. Decomposed paresthesia at baseline increased the risk of pain at follow-up (odds ratio [OR] 1.56; 95% confidence interval [CI] 1.18, 2.07), and decomposed pain at baseline predicted a higher frequency of pain at follow-up (OR 1.96 [95% CI 1.51, 2.58])., Conclusions: Paresthesias are a clinically significant predictor of incident pain at follow-up among aging PWH with DSP. Development of new therapies to encourage neuroregeneration might take advantage of this finding to choose individuals likely to benefit from treatment preventing incident pain., (© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
14. Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.
- Author
-
Nakasujja N, Vecchio AC, Saylor D, Lofgren S, Nakigozi G, Boulware DR, Kisakye A, Batte J, Mayanja R, Anok A, Reynolds SJ, Quinn TC, Pardo CA, Kumar A, Gray RH, Wawer MJ, Sacktor N, and Rubin LH
- Subjects
- Adult, Cohort Studies, Female, Humans, Male, Middle Aged, Uganda, Anti-HIV Agents therapeutic use, Depression etiology, HIV Infections complications, HIV Infections drug therapy, HIV Infections psychology
- Abstract
Depression is common following HIV infection and often improves after ART initiation. We aimed to identify distinct dimensions of depression that change following ART initiation in persons with HIV (PWH) with minimal comorbidities (e.g., illicit substance use) and no psychiatric medication use. We expected that dimensional changes in improvements in depression would differ across PWH. In an observational cohort in Rakai, Uganda, 312 PWH (51% male; mean age = 35.6 years) completed the Center for Epidemiologic Studies-Depression (CES-D) scale before and up to 2 years after ART initiation. Twenty-two percent were depressed (CES-D scores ≥ 16) pre-ART that decreased to 8% after ART. All CES-D items were used in a latent class analysis to identify subgroups with similar change phenotypes. Two improvement phenotypes were identified: affective-symptom improvement (n = 58, 19%) and mixed-symptom improvement (effort, appetite, irritability; n = 41, 13%). The affect-improvement subgroup improved on the greatest proportion of symptoms (76%). A third subgroup was classified as no-symptom changes (n = 213, 68%) as they showed no difference is symptom manifestation from baseline (93% did not meet depression criteria) to post-ART. Factors associated with subgroup membership in the adjusted regression analysis included pre-ART self-reported functional capacity, CD4 count, underweight BMI, hypertension, female sex(P's < 0.05). In a subset of PWH with CSF, subgroup differences were seen on Aβ-42, IL-13, and IL-12. Findings support that depression generally improves following ART initiation; however, when improvement is seen the patterns of symptom improvement differ across PWH. Further exploration of this heterogeneity and its biological underpinning is needed to evaluate potential therapeutic implications of these differences., (© 2021. Journal of NeuroVirology, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
15. Assessment, prevalence, and correlates of frailty among middle-aged adults with HIV in rural Uganda.
- Author
-
Vecchio A, Nakigozi G, Nakasujja N, Kisakye A, Batte J, Mayanja R, Anok A, Robertson K, Wawer MJ, Sacktor N, Rubin LH, and Saylor D
- Subjects
- Adult, Aged, Antiretroviral Therapy, Highly Active, Cross-Sectional Studies, Depression complications, Depression drug therapy, Depression epidemiology, Exercise physiology, Female, Frailty complications, Frailty drug therapy, Frailty epidemiology, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Humans, Male, Middle Aged, Neurocognitive Disorders complications, Neurocognitive Disorders drug therapy, Neurocognitive Disorders epidemiology, Prevalence, Risk Factors, Rural Population, Surveys and Questionnaires, Uganda epidemiology, Activities of Daily Living psychology, Anti-HIV Agents therapeutic use, Depression physiopathology, Frailty physiopathology, HIV Infections physiopathology, Neurocognitive Disorders physiopathology
- Abstract
We investigated the prevalence and risk factors for frailty among people with HIV (PWH) in rural Uganda (n = 55, 47% male, mean age 44 years). Frailty was defined according to the Fried criteria with self-reported physical activity level replacing the Minnesota Leisure Time Activity Questionnaire. Alternate classifications for physical activity utilized were the sub-Saharan Africa Activity Questionnaire and the International Physical Activity Questionnaire. Eleven participants (19%) were frail. Frail participants were older (p < 0.001), less likely to be on antiretroviral therapy (p = 0.03), and had higher rates of depression (p < .001) and HIV-associated neurocognitive disorder (p = 0.003). Agreement between physical activity measures was sub-optimal. Prevalence of frailty was high among PWH in rural Uganda, but larger sample sizes and local normative data are needed.
- Published
- 2021
- Full Text
- View/download PDF
16. Longitudinal 5-year prediction of cognitive impairment among men with HIV disease.
- Author
-
Oliveira NL, Kennedy EH, Tibshirani R, Levine A, Martin E, Munro C, Ragin AB, Rubin LH, Sacktor N, Seaberg EC, Weinstein A, and Becker JT
- Subjects
- Cohort Studies, Homosexuality, Male, Humans, Longitudinal Studies, Male, Cognitive Dysfunction diagnosis, Cognitive Dysfunction epidemiology, Cognitive Dysfunction etiology, HIV Infections complications, Sexual and Gender Minorities
- Abstract
Background: Although combination antiretroviral therapy reduced the prevalence of HIV-associated dementia, milder syndromes persist. Our goals were to predict cognitive impairment of the Multicenter AIDS Cohort Study (MACS) participants 5 years ahead and from a large pool of factors, select the ones that mostly contributed to our predictions., Design: Longitudinal, natural and treated history of HIV infection among MSM., Methods: The MACS is a longitudinal study of the natural and treated history of HIV disease in MSM; the neuropsychological substudy aims to characterize cognitive disorders in men with HIV disease., Results: We modeled on an annual basis the risk of cognitive impairment 5 years in the future. We were able to predict cognitive impairment at individual level with high precision and overperform default methods. We found that while a diagnosis of AIDS is a critical risk factor, HIV infection per se does not necessarily convey additional risk. Other infectious processes, most notably hepatitis B and C, are independently associated with increased risk of impairment. The relative importance of an AIDS diagnosis diminished across calendar time., Conclusion: Our prediction models are a powerful tool to help clinicians address dementia in early stages for MACS paticipants. The strongest predictors of future cognitive impairment included the presence of clinical AIDS and hepatitis B or C infection. The fact that the pattern of predictive power differs by calendar year suggests a clinically critical change to the face of the epidemic., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda.
- Author
-
Vecchio AC, Williams DW, Xu Y, Yu D, Saylor D, Lofgren S, O'Toole R, Boulware DR, Nakasujja N, Nakigozi G, Kisakye A, Batte J, Mayanja R, Anok A, Reynolds SJ, Quinn TC, Gray RH, Wawer MJ, Sacktor N, and Rubin LH
- Subjects
- Adult, Biomarkers, Cohort Studies, Female, Humans, Male, Neuropsychological Tests, Uganda, Cognition, HIV Infections complications, HIV Infections drug therapy
- Abstract
People with HIV (PWH) taking antiretroviral therapy (ART) have persistent cognitive impairment. The prevalence of cognitive impairment is higher in women with HIV (WWH) compared to men with HIV (MWH), possibly due to sex differences in immune function. Here we report sex differences in cerebrospinal fluid (CSF) immune markers in relation to cognitive performance. A subset of 83 PWH on ART (52% WWH; mean age = 37.6 years, SD = 7.9) from the Rakai community cohort study Cohort and Rakai Health Sciences Program supported clinics in rural Uganda completed a neuropsychological (NP) assessment and a lumbar puncture. CSF was used to measure 16 cytokines/chemokines. Individual NP test z-scores were generated based on local normative data. A series of least absolute shrinkage and selection operator (lasso) regressions examined associations between CSF inflammatory markers and NP outcomes. Overall, there were no sex differences in CSF inflammatory marker levels. However, MWH displayed more associations between inflammatory markers and cognitive performance than WWH. Among MWH, inflammatory markers were associated with a number of cognitive domains, including attention, processing speed, fluency, executive function, learning and memory. MIP-1β, INF-γ, GM-CSF, IL-7 and IL-12p70 were associated with multiple domains. Among WWH, few inflammatory markers were associated cognition. Degree of associations between CSF inflammatory biomarkers and cognitive performance varied by sex in this young, ART-treated, Ugandan cohort. Further investigation into sex-specific inflammatory mechanisms of cognitive impairment among PWH is warranted to inform sex-specific management strategies., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
18. Evaluation of a screening tool for the identification of neurological disorders in rural Uganda.
- Author
-
Tran A, Thakur KT, Nakasujja N, Nakigozi G, Kisakye A, Batte J, Mayanja R, Anok A, Gray RH, Wawer MJ, Rubin LH, Sacktor N, and Saylor D
- Subjects
- Adult, Cohort Studies, Female, Humans, Male, Mass Screening, Prevalence, Rural Population, Uganda epidemiology, HIV Infections diagnosis, HIV Infections epidemiology, Nervous System Diseases diagnosis, Nervous System Diseases epidemiology
- Abstract
Background: Neurological disorders are common in sub-Saharan African, but accurate neuroepidemiologic data are lacking from the region. We assessed a neuroepidemiological screening tool in a rural Ugandan cohort with high HIV prevalence., Methods: Participants were recruited from the Rakai Neurology Study in rural Rakai District, Uganda. A nurse administered the tool and a sociodemographic survey. 100 participants returned for validation examinations by a neurologist (validation cohort). The diagnostic utility and validity of the instrument were calculated and characteristics of those with and without neurological disorders compared., Results: The tool was administered to 392 participants, 48% female, 33% people with HIV, average age 35.1 ± 8.5 years. 33% of the study cohort screened positive for neurologic disorders. These participants were older [mean (SD): 38.3 (9.7) vs. 33.5 (7.1) years, p < 0.001], had a lower Karnofsky score [89.8 (8.4) vs. 93.9 (7.5), p < 0.001] and had a lower body mass index [21.8 (3.3) vs. 22.8 (3.7), p = 0.007] than those who screened negative. Amongst the validation cohort, 54% had a neurological abnormality of which 46% were symptomatic. The tool was 57% sensitive and 74% specific for detecting any neurological abnormality and 80% sensitive and 69% specific for symptomatic abnormalities., Conclusions: We found a lower sensitivity and similar specificity for the screening tool compared with two previous studies. The lower validity in this study was likely due in part to the high percentage of asymptomatic neurological abnormalities detected. This screening tool will require further refinement and cultural contextualization before it can be widely implemented across new populations., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Neurocognitive Complications of HIV Infection in Low-Income Countries.
- Author
-
Vecchio A, Sacktor N, Saylor D, and Robertson K
- Subjects
- Humans, Prevalence, Young Adult, Cognitive Dysfunction, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology
- Abstract
There is a paucity of information on neurocognitive dysfunction in individuals with HIV in resource-limited regions, despite the fact that these areas have the greatest burden of infection. HIV-associated neurocognitive disorder (HAND) remains a common complication of HIV despite the use of effective antiretroviral therapy (ART). HAND is a major cause of morbidity of HIV+ individuals and is estimated to be the most prevalent form of neurocognitive impairment worldwide in young adults. This finding has drastic implications for the productivity and social engagement of young adults in the development of industry, education, and healthcare, which is particularly relevant in low-income countries. Building an infrastructure to examine the neurological and neuropsychological characteristics of HIV+ individuals in resource-limited settings (RLS) can advance the understanding of the unique contributing factors of HIV-1 clades in these regions of high prevalence, improve neurological monitoring, explore the CNS HIV reservoir, and provide key information on prevention/interventions to help manage/improve these neurological and neuropsychological complications., (© 2019. Springer Nature Switzerland AG.)
- Published
- 2021
- Full Text
- View/download PDF
20. NIH Workshop on HIV-Associated Comorbidities, Coinfections, and Complications: Summary and Recommendation for Future Research.
- Author
-
Pahwa S, Deeks S, Zou S, Tomitch N, Miller-Novak L, Caler E, Justice A, Sacktor N, Gabuzda D, Hunt PW, Brown T, Kurth A, Baral S, Mugavero M, Mayer KH, Mendenhall E, Detels R, and Mutabazi V
- Subjects
- Aging, Biomarkers, Coinfection complications, Coinfection therapy, Comorbidity, Education, HIV Infections complications, HIV Infections therapy, Humans, Income, Microbiota, Research Personnel, Virome, Coinfection epidemiology, HIV Infections epidemiology, Research
- Abstract
Background: With potent antiretroviral therapy and simplified regimens, people living with HIV (PWH) are achieving near-normal lifespans but not necessarily a normal health span or healthy aging. PWH have a higher than expected risk of developing a number of non-AIDS comorbidities, coinfections, and complications (CCC), often against a background of stigma, poverty, and isolation., Setting: To gain a better understanding of research needs for HIV-associated CCC, the NIH convened a 2-day workshop (HIV-associated CCC, or HIV ACTION)., Methods: A cross-institute NIH planning committee identified 6 key research areas: epidemiology and population research, pathogenesis and basic science research, clinical research, implementation science research, syndemics research and international research in low and middle income countries. Investigators were selected to lead working groups (WGs) to assess the state-of-the-art and identify 3-5 priority areas in each field before the workshop. A 2-day program at the NIH was developed which included presentations by invited experts and WG members., Results: Over 400 participants attended the workshop. After general and individual WG discussions, the most pressing gaps, questions, or proposed action items were identified. Priority lists of pressing research issues were presented by cochairs of each WG. A detailed report is posted at the NHLBI website. This article reports the streamlined priority list and a summary of WG discussions to inform investigators of current priorities in the field., Conclusion: Collaborative efforts of many disciplines are needed to improve the health and wellbeing of PWH. Several common themes emerged across WG representing potential priorities for investigators and recommendations for the NIH.
- Published
- 2021
- Full Text
- View/download PDF
21. Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research.
- Author
-
Levine A, Sacktor N, and Becker JT
- Subjects
- Humans, AIDS Dementia Complex virology, COVID-19 complications, COVID-19 virology, Nervous System Diseases virology, SARS-CoV-2
- Abstract
The virology of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the human immune response to the virus are under vigorous investigation. There are now several reports describing neurological symptoms in individuals who develop coronavirus disease 2019 (COVID-19), the syndrome associated with SARS-CoV-2 infection. The prevalence, incidence, and clinical course of these symptoms will become clearer in the coming months and years through epidemiological studies. However, the long-term neurological and cognitive consequence of SARS-CoV-2 infection will remain conjectural for some time and will likely require the creation of cohort studies that include uninfected individuals. Considering the early evidence for neurological involvement in COVID-19 it may prove helpful to compare SARS-CoV-2 with another endemic and neurovirulent virus, human immunodeficiency virus-1 (HIV-1), when designing such cohort studies and when making predictions about neuropsychological outcomes. In this paper, similarities and differences between SARS-CoV-2 and HIV-1 are reviewed, including routes of neuroinvasion, putative mechanisms of neurovirulence, and factors involved in possible long-term neuropsychological sequelae. Application of the knowledge gained from over three decades of neuroHIV research is discussed, with a focus on alerting researchers and clinicians to the challenges in determining the cause of neurocognitive deficits among long-term survivors.
- Published
- 2020
- Full Text
- View/download PDF
22. Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
- Author
-
Vecchio A, Robertson K, Saylor D, Nakigozi G, Nakasujja N, Kisakye A, Batte J, Mayanja R, Anok A, Reynolds SJ, Quinn TC, Gray R, Wawer MJ, Sacktor N, and Rubin LH
- Subjects
- Adult, Alkynes adverse effects, Alkynes therapeutic use, Benzoxazines adverse effects, Benzoxazines therapeutic use, Cognition, Cohort Studies, Cyclopropanes adverse effects, Cyclopropanes therapeutic use, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Rural Population, Uganda epidemiology, Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, HIV Infections complications, HIV Infections epidemiology, HIV-1, Neurocognitive Disorders chemically induced
- Abstract
Background: HIV-associated neurocognitive disorders remain prevalent despite effective antiretroviral therapy (ART), but there are limited longitudinal data on people living with HIV (PLWH) in sub-Saharan Africa. We examined neuropsychological (NP) performance in PLWH in a longitudinal study in Uganda., Methods: Participants enrolled through the Rakai Community Cohort Study (400 ART-naive PLWH and 400 matched HIV-negative persons) were administered NP assessments. In 2017, PLWH who had initiated ART underwent a 2-year follow-up assessment. Demographically adjusted Z-scores for each NP test were established using data from the HIV- controls. Multivariable linear and logistic regressions were conducted to examine group differences in NP performance. Mixed-effects regressions were conducted to examine ART-related changes in NP outcomes., Results: Of 333 PLWH who returned for their 2-year follow-up visit, 312 (94%) had initiated ART. Those on ART had a mean age of 35.6 years (SD ± 8.5 years) and mean education of 5.4 years (SD ± 3.3 years); 49% were women. ART-associated NP improvements occurred in verbal learning and memory (P's < 0.05), motor (P's < 0.01), and some measures of processing speed (P = 0.002), whereas there were declines in attention/working memory (P's < 0.001) and semantic fluency (P < 0.001). Pre-ART CD4 count and efavirenz use were associated with a more impaired change in NP performance., Conclusions: PLWH in this resource-limited setting showed improved neurocognitive performance on most NP tests after ART initiation. However, the declines in attention/working memory and fluency performance, as well as relationship to efavirenz, warrant further study.
- Published
- 2020
- Full Text
- View/download PDF
23. Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV.
- Author
-
Ellis RJ, Letendre SL, Atkinson JH, Clifford D, Collier AC, Gelman BB, Marra C, McCutchan JA, Morgello S, Sacktor N, Tang B, and Heaton RK
- Abstract
Background and Objectives: People with HIV (PWH) often suffer from depressive symptoms which have a deleterious impact on numerous domains including antiretroviral adherence and quality of life. In the general population, a treatment-resistant phenotype of depression is associated with systemic inflammation, which is of considerable importance as it responds favorably to anti-inflammatory medications. Aging PWH experience increasing inflammation. We sought to evaluate the impact of chronic inflammation in aging PWH on depressed mood., Methods: PWH were recruited at 6 U.S. academic medical centers. Depressed mood was assessed using the Beck Depression Inventory (BDI)-II. Inflammatory biomarkers measured at the 12-year follow-up visit in blood plasma using immunoassays were neopterin, sTNFRII, d-dimer, IL-6, CRP, MCP-1, sCD14 and sCD40L. Factor analyses with oblique Equamax rotation were employed to reduce the dimensionality of the biomarkers., Results: Participants were 78 PWH, 14 (17.9%) women, 40 (51.3%) non-White, mean age 55.3 (±SD 8.29), with a nadir and current CD4 of 134 (IQR 36, 204) and 567 (316, 797), respectively. 80.5% were virally suppressed. A factor analysis of the eight inflammatory biomarkers in plasma at the 12-year follow-up visit yielded 3 Factors, with Factor 1 loading on neopterin and sTNFRII, Factor 2 loading on d-dimer, IL-6 and CRP, and Factor 3 loading on sCD40L (MCP-1 and sCD14 did not appear in any of the factors). Univariate regressions of each factor vs BDI-II scores yielded significance only for Factor 2 (r = 0.295; p = 0.0083 (Bonferroni-adjusted p = 0.0261). Of the Factor 2 component biomarkers, BDI-II scores correlated significantly with d-dimer and IL-6, but not CRP. Women had worse BDI-II scores (p = 0.0127). In a logistic regression with sex and Factor 2, both variables were significant (sex p = 0.0246, Factor 2 p = 0.0168). The relationship between Factor 2 and BDI was significant for men (r = 0.348 [95% CI 0.111, 0.547]; p = 0.0049), but not women (r = 0.0580 95% CI -0.488, 0.571]; p = 0.844). Viral suppression was not significant in the multivariate model., Conclusions: Some PWH with depressed mood have elevated markers of inflammation in blood. Men showed this relationship, while women did not. Together with previous findings that an inflammatory depression phenotype responds to treatment with anti-inflammatory medications, our findings suggest that treatment with anti-inflammatory medications might benefit at least a subset of depressed PWH who have a high inflammatory biomarker profile, as well as poor response to antidepressant medications alone, and that the pathophysiology of depression in men and women with HIV may differ., Competing Interests: The authors report no conflicts of interest, (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
24. Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV.
- Author
-
Ellis RJ, Diaz M, Sacktor N, Marra C, Collier AC, Clifford DB, Calcutt N, Fields JA, Heaton RK, and Letendre SL
- Subjects
- Activities of Daily Living, Adult, Female, Follow-Up Studies, HIV Infections diagnosis, HIV Infections epidemiology, Humans, Incidence, Male, Middle Aged, Neuralgia diagnosis, Neuralgia epidemiology, Polyneuropathies diagnosis, Polyneuropathies epidemiology, Prevalence, Protective Factors, Quality of Life, Risk Factors, Body Mass Index, HIV Infections complications, Neuralgia etiology, Polyneuropathies etiology, Severity of Illness Index, Unemployment statistics & numerical data
- Abstract
Objective: Distal sensory polyneuropathy (DSP) and neuropathic pain are important clinical concerns in virally suppressed people with HIV. We determined how these conditions evolved, what factors influenced their evolution, and their clinical impact., Methods: Ambulatory, community-dwelling HIV seropositive individuals were recruited at six research centers. Clinical evaluations at baseline and 12 years later determined neuropathy signs and distal neuropathic pain (DNP). Additional assessments measured activities of daily living and quality of life (QOL). Factors potentially associated with DSP and DNP progression included disease severity, treatment, demographics, and co-morbidities. Adjusted odds ratios were calculated for follow-up neuropathy outcomes., Results: Of 254 participants, 21.3% were women, 57.5% were non-white. Mean baseline age was 43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173 participants initially pain-free, 42 (24.3%) had incident neuropathic pain. Baseline risk factors for incident pain included unemployment (OR [95% CI], 5.86 [1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per 10-units). Participants with neuropathic pain at follow-up had significantly worse QOL and greater dependence in activities of daily living than those who remained pain-free., Interpretation: HIV DSP and neuropathic pain increased in prevalence and severity over 12 years despite high rates of viral suppression. The high burden of neuropathy included disability and poor life quality. However, substantial numbers remained pain-free despite clear evidence of neuropathy on exam. Protective factors included being employed and having a lower BMI. Implications for clinical practice include promotion of lifestyle changes affecting reversible risk factors., (© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2020
- Full Text
- View/download PDF
25. Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings.
- Author
-
Vecchio AC, Marra CM, Schouten J, Jiang H, Kumwenda J, Supparatpinyo K, Hakim J, Sacktor N, Campbell TB, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firnhaber C, Hosseinipour MC, Mngqibisa R, Hall C, Cinque P, and Robertson K
- Subjects
- Aged, CD4 Lymphocyte Count, Humans, HIV Infections complications, HIV Infections drug therapy, HIV Seropositivity, HIV-1, Peripheral Nervous System Diseases epidemiology
- Abstract
Background: Distal sensory peripheral neuropathy (DSPN) is a complication of human immunodeficiency virus (HIV). We estimate DSPN prevalence in 7 resource-limited settings (RLSs) for combination antiretroviral therapy (cART)-naive people living with HIV (PLWH) compared with matched participants not living with HIV and in PLWH virally suppressed on 1 of 3 cART regimens., Methods: PLWH with a CD4+ count <300 cells/mm3 underwent standardized neurological examination and functional status assessments before and every 24 weeks after starting cART. Matched individuals not living with HIV underwent the same examinations once.Associations between covariates with DSPN at entry were assessed using the χ2 test, and virally suppressed PLWH were assessed using generalized estimating equations., Results: Before initiating cART, 21.3% of PLWH had DSPN compared with 8.5% of people not living with HIV (n = 2400; χ2(df = 1) = 96.5; P < .00001). PLWH with DSPN were more likely to report inability to work [χ2(df = 1) = 10.6; P = .001] and depression [χ2(df = 1) = 8.9; P = .003] than PLWH without DSPN. Overall prevalence of DSPN among those virally suppressed on cART decreased: 20.3%, week 48; 15.3%, week 144; and 10.3%, week 192. Incident DSPN was seen in 127 PLWH. Longitudinally, DSPN was more likely in older individuals (P < .001) and PLWH with less education (P = .03). There was no significant association between cART regimen and DSPN., Conclusions: Although the prevalence of DSPN decreased following cART initiation in PLWH, further research could identify strategies to prevent or ameliorate residual DSPN after initiating cART in RLSs., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
26. Brain structural correlates of trajectories to cognitive impairment in men with and without HIV disease.
- Author
-
Popov M, Molsberry SA, Lecci F, Junker B, Kingsley LA, Levine A, Martin E, Miller E, Munro CA, Ragin A, Seaberg E, Sacktor N, and Becker JT
- Subjects
- Brain diagnostic imaging, Cohort Studies, Gray Matter diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Cognitive Dysfunction diagnostic imaging, HIV Infections complications, HIV Infections diagnostic imaging
- Abstract
There are distinct trajectories to cognitive impairment among participants in the Multicenter AIDS Cohort Study (MACS). Here we analyzed the relationship between regional brain volumes and the individual trajectories to impairment in a subsample (n = 302) of the cohort. 302 (167 HIV-infected; mean age = 55.7 yrs.; mean education: 16.2 yrs.) of the men enrolled in the MACS MRI study contributed data to this analysis. We used voxel-based morphometry (VBM) to segment the brain images to analyze gray and white matter volume at the voxel-level. A Mixed Membership Trajectory Model had previously identified three distinct profiles, and each study participant had a membership weight for each of these three trajectories. We estimated VBM model parameters for 100 imputations, manually performed the post-hoc contrasts, and pooled the results. We examined the associations between brain volume at the voxel level and the MMTM membership weights for two profiles: one considered "unhealthy" and the other considered "Premature aging." The unhealthy profile was linked to the volume of the posterior cingulate gyrus/precuneus, the inferior frontal cortex, and the insula, whereas the premature aging profile was independently associated with the integrity of a portion of the precuneus. Trajectories to cognitive impairment are the result, in part, of atrophy in cortical regions linked to normal and pathological aging. These data suggest the possibility of predicting cognitive morbidity based on patterns of CNS atrophy.
- Published
- 2020
- Full Text
- View/download PDF
27. Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals.
- Author
-
Mohamed M, Skolasky RL, Zhou Y, Ye W, Brasic JR, Brown A, Pardo CA, Barker PB, Wong DF, and Sacktor N
- Subjects
- Aged, Aniline Compounds, Biological Transport, Brain, Cognitive Dysfunction metabolism, Cognitive Dysfunction physiopathology, Cognitive Dysfunction virology, Cross-Sectional Studies, Ethylene Glycols, Female, Fluorine Radioisotopes, HIV growth & development, HIV Infections metabolism, HIV Infections physiopathology, HIV Infections virology, Humans, Male, Middle Aged, Positron-Emission Tomography, Severity of Illness Index, Amyloid beta-Peptides metabolism, Brain Mapping methods, Cognitive Dysfunction diagnostic imaging, HIV pathogenicity, HIV Infections diagnostic imaging
- Abstract
The causes of cognitive impairment among older HIV+ individuals may overlap with causes among elderly HIV seronegative (HIV-) individuals. The objective of this study was to determine if beta-amyloid (Aβ) deposition measured by [
18 F] AV-45 (florbetapir) positron emission tomography (PET) is increased in older HIV+ individuals compared to HIV- individuals. Forty-eight HIV+ and 25 HIV- individuals underwent [18 F] AV-45 PET imaging. [18 F] AV-45 binding to Aβ was measured by standardized uptake value ratios (SUVR) relative to the cerebellum in 16 cortical and subcortical regions of interest. Global and regional cortical SUVRs were compared by (1) serostatus, (2) HAND stage, and (3) age decade, comparing individuals in their 50s and > 60s. There were no differences in median global cortical SUVR stratified by HIV serostatus or HAND stage. The proportion of HIV+ participants in their 50s with elevated global amyloid uptake (SUVR > 1.40) was significantly higher than the proportion in HIV- participants (67% versus 25%, p = 0.04), and selected regional SUVR values were also higher (p < 0.05) in HIV+ compared to HIV- participants in their 50s. However, these group differences were not seen in participants in their 60s. In conclusion, PET imaging found no differences in overall global Aβ deposition stratified by HIV serostatus or HAND stage. Although there was some evidence of increased Aβ deposition in HIV+ individuals in their 50s compared to HIV- individuals which might indicate premature aging, the most parsimonious explanation for this is the relatively small sample size in this cross-sectional cohort study.- Published
- 2020
- Full Text
- View/download PDF
28. The Veterans Aging Cohort Study Index is not associated with HIV-associated neurocognitive disorders in Uganda.
- Author
-
Awori V, Nakigozi G, Kisakye A, Batte J, Anok A, Mayanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Sacktor N, and Saylor D
- Subjects
- Adult, Cohort Studies, Female, Humans, Male, Uganda, Veterans, AIDS Dementia Complex diagnosis, Severity of Illness Index
- Abstract
The Veterans Aging Cohort Study (VACS) Index has been associated with HIV-associated neurocognitive disorder (HAND) in some populations but has not been studied in sub-Saharan Africa. We investigated whether the VACS Index is associated with HAND in a rural population in Rakai, Uganda. HIV-infected (HIV+) adults on antiretroviral therapy underwent a neurocognitive battery for determination of HAND stage using Frascati criteria. VACS component scores were recorded for all participants. Out of 156 study participants, HAND stages were 49% normal cognition, 15% asymptomatic neurocognitive impairment, 31% minor neurocognitive disorder, and 7% HIV-associated dementia. There was no significant association between VACS Index and any HAND stage. In this first study of the VACS Index in sub-Saharan Africa, we found no association between VACS Index score and HAND.
- Published
- 2020
- Full Text
- View/download PDF
29. Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder.
- Author
-
Molinaro M, Sacktor N, Nakigozi G, Anok A, Batte J, Kisakye A, Myanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, and Saylor D
- Subjects
- Adult, Anti-Retroviral Agents adverse effects, Anti-Retroviral Agents therapeutic use, Cohort Studies, Female, Humans, Longitudinal Studies, Male, AIDS Dementia Complex diagnosis, Neuropsychological Tests standards
- Abstract
Background: We assessed the utility of the International HIV Dementia Scale (IHDS) in detecting HIV-associated neurocognitive disorder (HAND) in Uganda in antiretroviral (ART)-naïve and ART-experienced adults., Setting: A longitudinal observational cohort study in Rakai, Uganda., Methods: Three hundred ninety-nine HIV+ ART-naïve adults underwent neurological, functional status, and neuropsychological assessments including the IHDS. Three hundred twelve participants who initiated ART were re-evaluated after 2 years. HAND stages [asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia (HAD)] were determined based on Frascati criteria using local normative data. Sensitivity, specificity, and area under the ROC curve were determined for various IHDS thresholds (≤9, ≤ 9.5, and ≤10)., Results: At baseline, the participants' mean age was 35 years (SD ± 8), 53% were men, and 84% had less than a high school education. At baseline, sensitivity for detecting any HAND stage, symptomatic HAND [mild neurocognitive disorder, HAD], and HAD alone were maximized at IHDS ≤10 (81%, 83%, 92%, respectively). Among 312 individuals who returned for the 2-year follow-up and had initiated ART, a score of ≤10 provided a lower or equal sensitivity for detecting different stages of HAND (all HAND: 70%; symptomatic HAND: 75%; HAD: 94%). The area under the ROC curve was higher for ART-experienced versus ART-naïve individuals., Conclusions: The IHDS is a potentially useful screening tool for neurocognitive impairment in rural Uganda for both ART-naïve and ART-experienced adults. A cutoff ≤10 demonstrates higher sensitivity for more severe HAND stages compared with less severe HAND. Future studies should focus on potential modifications to the IHDS to improve its specificity.
- Published
- 2020
- Full Text
- View/download PDF
30. The neurologic phenotype of South African patients with HIV-associated neurocognitive impairment.
- Author
-
Anderson SG, McCaul M, Khoo S, Wiesner L, Sacktor N, Joska JA, and Decloedt EH
- Abstract
Background: The neurologic manifestations of HIV include a spectrum of HIV-associated neurocognitive disorders, as well as a cluster of neurologic symptoms and signs. The neurologic manifestations have been modified but not eradicated by antiretroviral therapy (ART). We describe the neurologic phenotype in South African patients with predominant HIV-1 subtype C infection on ART and its association with neurocognitive impairment and efavirenz and 8-hydroxy-efavirenz concentrations., Methods: We conducted a cross-sectional analysis of the neurologic examination findings of HIV+ patients with neurocognitive impairment and used multiple linear regression to explore associations with neurocognitive impairment, efavirenz, and 8-hydroxy-efavirenz pharmacokinetics (plasma and CSF)., Results: We included 80 participants established on ART (median 40 months) of which 72 (90%) were female. The median age was 35 (interquartile range [IQR], 32-42) and the median Global Deficit Score was 0.94 (IQR 0.63-1.36). We found associations between neurocognitive impairment and neurologic signs: gait (slow walking speed [ p = 0.03; R
2 = 0.06], gait ataxia [ p < 0.01; R2 = 0.21], and abnormal gait appearance [ p < 0.01; R2 = 0.18]); coordination (upper limb bradykinesia [ p < 0.01; R2 = 0.10] and lower limb bradykinesia [ p = 0.01; R2 = 0.10]); reflexes (jaw jerk [ p = 0.04; R2 = 0.05] and palmomental response [ p = 0.03; R2 = 0.06]); ocular signs (impaired smooth pursuit [ p = 0.01; R2 = 0.09] and impaired saccades [ p < 0.01; R2 = 0.15]); and motor signs (spasticity [ p ≤ 0.01; R2 = 0.15] and muscle weakness [ p = 0.01; R2 = 0.08]). No significant associations were found between plasma and CSF efavirenz or 8-hydroxy efavirenz concentrations and any neurologic sign., Conclusion: We found that individual neurologic signs were associated with neurocognitive impairment in South African HIV+ patients with predominant HIV-1 subtype C infection on ART and could be used in clinical practice to assess severity., Registration Number: PACTR201310000635418., (© 2019 American Academy of Neurology.)- Published
- 2020
- Full Text
- View/download PDF
31. Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities.
- Author
-
Campbell LM, Fennema-Notestine C, Saloner R, Hussain M, Chen A, Franklin D, Umlauf A, Ellis RJ, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, McCutchan JA, Letendre S, Grant I, and Heaton RK
- Subjects
- Activities of Daily Living, Adult, Cerebral Cortex diagnostic imaging, Cerebral Cortex pathology, Cross-Sectional Studies, Female, Humans, Inflammation immunology, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Middle Aged, Neurocognitive Disorders physiopathology, HIV Infections complications, Neurocognitive Disorders diagnosis, Neurocognitive Disorders etiology, Neurocognitive Disorders pathology, Neuroimaging, Practice Guidelines as Topic standards
- Abstract
Objective: Frascati international research criteria for HIV-associated neurocognitive disorders (HAND) are controversial; some investigators have argued that Frascati criteria are too liberal, resulting in a high false positive rate. Meyer et al. recommended more conservative revisions to HAND criteria, including exploring other commonly used methodologies for neurocognitive impairment (NCI) in HIV including the global deficit score (GDS). This study compares NCI classifications by Frascati, Meyer, and GDS methods, in relation to neuroimaging markers of brain integrity in HIV., Method: Two hundred forty-one people living with HIV (PLWH) without current substance use disorder or severe (confounding) comorbid conditions underwent comprehensive neurocognitive testing and brain structural magnetic resonance imaging and magnetic resonance spectroscopy. Participants were classified using Frascati criteria versus Meyer criteria: concordant unimpaired [Frascati(Un)/Meyer(Un)], concordant impaired [Frascati(Imp)/Meyer(Imp)], or discordant [Frascati(Imp)/Meyer(Un)] which were impaired via Frascati criteria but unimpaired via Meyer criteria. To investigate the GDS versus Meyer criteria, the same groupings were utilized using GDS criteria instead of Frascati criteria., Results: When examining Frascati versus Meyer criteria, discordant Frascati(Imp)/Meyer(Un) individuals had less cortical gray matter, greater sulcal cerebrospinal fluid volume, and greater evidence of neuroinflammation (i.e., choline) than concordant Frascati(Un)/Meyer(Un) individuals. GDS versus Meyer comparisons indicated that discordant GDS(Imp)/Meyer(Un) individuals had less cortical gray matter and lower levels of energy metabolism (i.e., creatine) than concordant GDS(Un)/Meyer(Un) individuals. In both sets of analyses, the discordant group did not differ from the concordant impaired group on any neuroimaging measure., Conclusions: The Meyer criteria failed to capture a substantial portion of PLWH with brain abnormalities. These findings support continued use of Frascati or GDS criteria to detect HIV-associated CNS dysfunction.
- Published
- 2020
- Full Text
- View/download PDF
32. Letter to the Editor.
- Author
-
Abassi M and Sacktor N
- Subjects
- Biomarkers, Humans, Uganda, HIV Infections, Neurocognitive Disorders
- Published
- 2019
- Full Text
- View/download PDF
33. Interleukin-6 is associated with mortality and neuropsychiatric outcomes in antiretroviral-naïve adults in Rakai, Uganda.
- Author
-
Saylor D, Kumar A, Nakigozi G, Anok A, Batte J, Kisakye A, Mayanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Pardo CA, and Sacktor N
- Subjects
- AIDS Dementia Complex mortality, Adult, CD4 Lymphocyte Count, Cohort Studies, Depression immunology, Female, HIV Infections mortality, Humans, Longitudinal Studies, Male, Uganda, AIDS Dementia Complex immunology, HIV Infections complications, HIV Infections immunology, Interleukin-6 immunology
- Abstract
Serum interleukin-6 (IL-6) and D-dimer have been associated with multiple adverse outcomes in HIV-infected (HIV+) individuals, but their association with neuropsychiatric outcomes, including HIV-associated neurocognitive disorder (HAND) and depression, headaches, and peripheral neuropathy have not been investigated. Three hundred ninety-nine HIV+ antiretroviral therapy (ART)-naïve adults in Rakai, Uganda, were enrolled in a longitudinal cohort study and completed a neurological evaluation, neurocognitive assessment, and venous blood draw. Half of the participants had advanced immunosuppression (CD4 count < 200 cells/μL), and half had moderate immunosuppression (CD4 count 350-500 cells/μL). All-cause mortality was determined by verbal autopsy within 2 years. HAND was determined using Frascati criteria, and depression was defined by the Center for Epidemiologic Studies-Depression (CES-D) scale. Neuropathy was defined as the presence of > 1 neuropathy symptom and > 1 neuropathy sign. Headaches were identified by self-report. Serum D-dimer levels were determined using ELISA and IL-6 levels using singleplex assays. Participants were 53% male, mean age 35 + 8 years, and mean education 5 + 3 years. Participants with advanced immunosuppression had significantly higher levels of IL-6 (p < 0.001) and a trend toward higher D-dimer levels (p = 0.06). IL-6 was higher among participants with HAND (p = 0.01), with depression (p = 0.03) and among those who died within 2 years (p = 0.001) but not those with neuropathy or headaches. D-dimer did not vary significantly by any outcome. Systemic inflammation as measured by serum IL-6 is associated with an increased risk of advanced immunosuppression, all-cause mortality, HAND, and depression but not neuropathy or headaches among ART-naïve HIV+ adults in rural Uganda.
- Published
- 2019
- Full Text
- View/download PDF
34. Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy.
- Author
-
Henderson LJ, Johnson TP, Smith BR, Reoma LB, Santamaria UA, Bachani M, Demarino C, Barclay RA, Snow J, Sacktor N, Mcarthur J, Letendre S, Steiner J, Kashanchi F, and Nath A
- Subjects
- Female, HIV Infections virology, HIV Long Terminal Repeat, HIV-1 genetics, Humans, Male, Middle Aged, Viral Load, HIV Infections drug therapy, RNA, Viral cerebrospinal fluid, Response Elements, Transcription, Genetic, Transcriptional Activation, tat Gene Products, Human Immunodeficiency Virus cerebrospinal fluid
- Abstract
Objective: The aim of this study was to measure the protein concentration and biological activity of HIV-1 Tat in cerebrospinal fluid (CSF) of individuals on suppressive antiretroviral therapy (ART)., Design: CSF was collected from 68 HIV-positive individuals on ART with plasma viral load less than 40 copies/ml, and from 25 HIV-negative healthy controls. Duration of HIV infection ranged from 4 to more than 30 years., Methods: Tat levels in CSF were evaluated by an ELISA. Tat protein and viral RNA were quantified from exosomes isolated from CSF, followed by western blot or quantitative reverse transcription PCR, respectively. Functional activity of Tat was assessed using an LTR transactivation assay., Results: Tat protein was detected in 36.8% of CSF samples from HIV-positive patients. CSF Tat concentration increased in four out of five individuals after initiation of therapy, indicating that Tat was not inhibited by ART. Similarly, exosomes from 34.4% of CSF samples were strongly positive for Tat protein and/or TAR RNA. Exosomal Tat retained transactivation activity in a CEM-LTR reporter assay in 66.7% of samples assayed, which indicates that over half of the Tat present in CSF is functional. Presence of Tat in CSF was highly associated with previous abuse of psychostimulants (cocaine or amphetamines; P = 0.01) and worse performance in the psychomotor speed (P = 0.04) and information processing (P = 0.02) cognitive domains., Conclusion: Tat and TAR are produced in the central nervous system despite adequate ART and are packaged into CSF exosomes. Tat remains biologically active within this compartment. These studies suggest that Tat may be a quantifiable marker of the viral reservoir and highlight a need for new therapies that directly inhibit Tat.
- Published
- 2019
- Full Text
- View/download PDF
35. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.
- Author
-
Rubin LH, Saylor D, Nakigozi G, Nakasujja N, Robertson K, Kisakye A, Batte J, Mayanja R, Anok A, Lofgren SM, Boulware DR, Dastgheyb R, Reynolds SJ, Quinn TC, Gray RH, Wawer MJ, and Sacktor N
- Subjects
- AIDS Dementia Complex physiopathology, Adult, Biomarkers analysis, Cohort Studies, Female, HIV Infections complications, Humans, Male, Middle Aged, Phenotype, Uganda, AIDS Dementia Complex classification, AIDS Dementia Complex etiology, Anti-Retroviral Agents therapeutic use, HIV Infections drug therapy
- Abstract
Considerable heterogeneity exists in patterns of neurocognitive change in people with HIV (PWH). We examined heterogeneity in neurocognitive change trajectories from HIV diagnosis to 1-2 years post-antiretroviral therapy (ART). In an observational cohort study in Rakai, Uganda, 312 PWH completed a neuropsychological (NP) test battery at two-time points (ART-naïve, 1-2 years post-ART initiation). All NP outcomes were used in a latent profile analysis to identify subgroups of PWH with similar ART-related neurocognitive change profiles. In a subset, we examined subgroup differences pre-ART on cytokine and neurodegenerative biomarkers CSF levels. We identified four ART-related change subgroups: (1) decline-only (learning, memory, fluency, processing speed, and attention measures), (2) mixed (improvements in learning and memory but declines in attention and executive function measures), (3) no-change, or (4) improvement-only (learning, memory, and attention measures). ART-related NP outcomes that are most likely to change included learning, memory, and attention. Motor function measures were unchanged. Subgroups differed on eight of 34 pre-ART biomarker levels including interleukin (IL)-1β, IL-6, IL-13, interferon-γ, macrophage inflammatory protein-1β, matrix metalloproteinase (MMP)-3, MMP-10, and platelet-derived growth factor-AA. The improvement-only and mixed subgroups showed lower levels on these markers versus the no-change subgroup. These findings provide support for the need to disentangle heterogeneity in ART-related neurocognitive changes, to focus on higher-order cognitive processes (learning, memory, attention) as they were most malleable to change, and to better understand why motor function remained unchanged despite ART treatment. Group differences in pre-ART CSF levels provide preliminary evidence of biological plausibility of neurocognitive phenotyping.
- Published
- 2019
- Full Text
- View/download PDF
36. Cross-sectional analysis of cognitive function using multivariate normative comparisons in men with HIV disease.
- Author
-
Wang Z, Molsberry SA, Cheng Y, Kingsley L, Levine AJ, Martin E, Munro CA, Ragin A, Rubin LH, Sacktor N, Seaberg EC, and Becker JT
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Bisexuality, Cognition, Cognitive Dysfunction epidemiology, Cohort Studies, Cross-Sectional Studies, HIV Infections drug therapy, HIV-1 isolation & purification, Homosexuality, Male, Humans, Male, Middle Aged, Prevalence, Sensitivity and Specificity, United States epidemiology, Cognitive Dysfunction diagnosis, HIV Infections complications, HIV Infections psychology, Neuropsychological Tests
- Abstract
Background: Prevalence estimates of cognitive impairment in HIV disease vary widely. Here we used multivariate normative comparison (MNC) with identify individuals with impaired cognition, and to compare the results with those using the Frascati and Gisslén criteria., Methods: The current project used data collected before October 2014 from bisexual/gay men from the Multicenter AIDS Cohort Study. A total of 2904 men (mean age 39.7 years, 52.7% seropositive) had complete data in six cognitive domains at their first neuropsychological evaluation. T-scores were computed for each domain and the MNC was applied to detect impairment among seronegative and seropositive groups., Results: The MNC classified 6.26% of seronegative men as being impaired using a predetermined 5% false discovery rate. By contrast, the Frascati and the Gisslén criteria identified 24.54 and 11.36% of seronegative men as impaired. For seropositive men, the percentage impairment was 7.45, 25.73, and 11.69%, respectively, by the MNC, Frascati and Gisslén criteria. When we used seronegative men without medical comorbidities as the control group, the MNC, the Frascati and the Gisslén criteria identified 5.05, 27.07, and 4.21% of the seronegative men, and 4.34, 30.95, and 4.48% of the seropositive men as having cognitive impairment. For each method, serostatus was not associated with cognitive impairment., Conclusion: The MNC controls the false discovery rate and therefore avoids the low specificity that characterizes the Frascati and Gisslén criteria. More research is needed to evaluate the sensitivity of the MNC method in a seropositive population that may be sicker and older than the current study sample and that includes women.
- Published
- 2019
- Full Text
- View/download PDF
37. Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study.
- Author
-
Lu H, Surkan PJ, Irwin MR, Treisman GJ, Breen EC, Sacktor N, Stall R, Wolinsky SM, Jacobson LP, and Abraham AG
- Subjects
- Depression epidemiology, HIV Infections psychology, Humans, Male, Prevalence, Prospective Studies, United States epidemiology, Depression etiology, HIV Infections complications, Inflammation complications, Sexual and Gender Minorities psychology
- Abstract
Studies suggest that inflammation might be involved in the pathogenesis of depression. Individuals with human immunodeficiency virus (HIV) have a higher risk of depression and elevated inflammatory profiles. Despite this, research on the link between inflammation and depression among this high-risk population is limited. We examined a sample of men who have sex with men from the Multicenter AIDS Cohort Study in prospective analyses of the association between inflammation and clinically relevant depression symptoms, defined as scores >20 on Center for Epidemiological Studies Depression Scale. We included 1,727 participants who contributed 9,287 person-visits from 1984 to 2010 (8,218 with HIV (HIV+) and 1,069 without (HIV-)). Exploratory factor analysis (EFA) was used to characterize underlying inflammatory processes from 19 immune markers. Logistic regression with generalized estimating equations was used to evaluate associations between inflammatory processes and depressive symptoms stratified by HIV serostatus. Three EFA-identified inflammatory processes (EIPs) were identified. EIP-1 scores-described by soluble tumor necrosis factor receptor 2 (sTNF-R2), soluble interleukin-2 receptor α (sIL-2Rα), sCD27, B-cell activating factor, interferon γ-induced protein 10 (IP-10), soluble interleukin-6 receptor (sIL-6R), sCD14, and sGP130-were significantly associated with 9% higher odds of depressive symptoms in HIV+ participants (odds ratio = 1.09; 95% confidence interval: 1.03, 1.16) and 33% higher odds in HIV- participants (odds ratio = 1.33; 95% confidence interval: 1.09, 1.61). Findings suggest that immune activation might be involved in depression risk among both HIV+ and HIV- men who have sex with men., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
38. Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus-Infected Patients.
- Author
-
Dastgheyb RM, Sacktor N, Franklin D, Letendre S, Marcotte T, Heaton R, Grant I, McArthur JC, Rubin LH, and Haughey NJ
- Subjects
- Adult, Antirheumatic Agents therapeutic use, Cognition, Cognitive Dysfunction drug therapy, Cohort Studies, Electronic Data Processing, Executive Function, Female, Humans, Learning, Male, Memory, Short-Term, Mental Recall, Middle Aged, Neuropsychological Tests, Prevalence, Speech Disorders, Verbal Learning, Cognitive Dysfunction epidemiology, HIV Infections complications, Phenotype
- Abstract
Objective: The presentation of cognitive impairments in HIV-infected individuals has transformed since the introduction of antiretroviral therapies. Although the overall prevalence of cognitive impairments has not changed considerably, frank dementia is now infrequent, and milder forms of cognitive impairments predominate. Mechanistic insights to the underlying causes of these residual cognitive impairments have been elusive, in part due to the heterogenous etiology of cognitive dysfunction in this population. Here, we sought to categorize longitudinal change in HIV-infected patients based on the performance in specific cognitive domains., Design: This study consisted of 193 participants from the CHARTER cohort with detailed demographic, clinical, and neuropsychological testing data obtained from 2 study visits interspersed by ∼6 months. Cognitive testing assessed executive function, learning and delayed recall, working memory, verbal fluency, speed of information processing, and motor skills. Change scores were calculated for each domain between the 2 study visits. Dimension reduction and clustering was accomplished by principal component analysis of change scores and k-means clustering to identify cognitive domains that group together and groups of subjects with similar patterns of change., Results: We identified 4 distinct cognitive change phenotypes that included declines in: (1) verbal fluency, (2) executive function (3) learning and recall, and (4) motor function, with approximately equal numbers of participants in each phenotype., Conclusions: Each of the 4 cognitive change phenotypes identify deficits that imply perturbations in specific neural networks. Future studies will need to validate if cognitive change phenotypes are associated with alterations in associated neural pathways.
- Published
- 2019
- Full Text
- View/download PDF
39. Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study.
- Author
-
Rubin LH, Gustafson D, Hawkins KL, Zhang L, Jacobson LP, Becker JT, Munro CA, Lake JE, Martin E, Levine A, Brown TT, Sacktor N, and Erlandson KM
- Subjects
- Adult, Aged, Aged, 80 and over, Attention, Body Mass Index, Case-Control Studies, Humans, Male, Memory, Short-Term, Middle Aged, Movement, Obesity epidemiology, Waist Circumference, Cognitive Dysfunction epidemiology, HIV Infections epidemiology, Obesity, Abdominal epidemiology
- Abstract
Objective: Obesity is a common, modifiable cardiovascular and cerebrovascular risk factor. Among people with HIV, obesity may contribute to multisystem dysregulation including cognitive impairment. We examined body mass index (BMI) and central obesity (waist circumference [WC]) in association with domain-specific cognitive function and 10-year cognitive decline in men with HIV infection (MWH) vs HIV-uninfected (HIV-) men., Methods: A total of 316 MWH and 656 HIV- Multicenter AIDS Cohort Study participants ≥40 years at baseline, with neuropsychological testing every 2 years and concurrent BMI and WC measurements, were included. MWH were included if taking ≥2 antiretroviral agents and had HIV-1 RNA <400 copies/mL at >80% of visits. Mixed-effects models included all visits from 1996 to 2015, stratified by HIV serostatus, and adjusted for sociodemographic, behavioral, and clinical characteristics. At baseline and follow-up, 8% of MWH and 15% of HIV- men and 41% of MWH and 56% of HIV- men were ≥60 years, respectively., Results: Cross-sectionally, higher BMI was inversely associated with motor function in MWH and HIV- men, and attention/working memory in HIV- men. WC was inversely associated with motor function in MWH and HIV- men. Longitudinal associations indicated an obese BMI was associated with a less steep decline in motor function in MWH whereas in HIV- men, obesity was associated with a greater decline in motor function, learning, and memory. WC, or central obesity, showed similar patterns of associations., Conclusion: Higher adiposity is associated with lower cognition cross-sectionally and greater cognitive decline, particularly in HIV- men. Overweight and obesity may be important predictors of neurologic outcomes and avenues for prevention and intervention., (© 2019 American Academy of Neurology.)
- Published
- 2019
- Full Text
- View/download PDF
40. Caregiver versus self-reported activities of daily living among HIV-positive persons in Rakai, Uganda.
- Author
-
Kisakye A, Saylor D, Sacktor N, Nakigozi G, Nakasujja N, Robertson K, Anok A, Wawer M, and Gray R
- Subjects
- Adult, Aged, Case-Control Studies, Cognition, Cognitive Dysfunction etiology, Female, HIV Infections complications, HIV Infections ethnology, Humans, Male, Middle Aged, Neuropsychological Tests, Uganda epidemiology, Activities of Daily Living, Caregivers psychology, Cognitive Dysfunction psychology, HIV Infections psychology, HIV Seronegativity, Self Report
- Abstract
Assessment of an individual's functional status, as measured by activities of daily living (ADL), is an essential element in the diagnosis of HIV-associated neurocognitive disorders (HAND) but individuals with cognitive impairment may not accurately report ADL. We assessed agreement between self- and caregiver-reported ADL in HIV-positive persons. Antiretroviral therapy (ART)-naïve HIV-positive persons (n = 321) and HIV-negative controls (n = 134) in Rakai, Uganda, completed neurocognitive tests and an ADL questionnaire. Co-resident relatives ("caregivers") were independently administered the ADL questionnaire to determine their perception of the participant's ADL. The relationship between neurocognitive impairment and participant-caregiver agreement was assessed using kappa statistics. Regression was used to estimate adjusted prevalence ratios (AdjPR) of participant-caregiver agreement on disability scores. Relative to HIV-negative adults, HIV-positive participants scoring at least 1 standard deviation (SD) below the norm on 2 or more neurocognitive tests were classified as having mild neurocognitive impairment and those scoring at least 2 SD below the norm on 2 or more neurocognitive tests were classified as having moderate-to-severe. Mean age was 36 years (SD 8.9), and 53% of participants were male. The rate of ADL agreement between participants and caregivers was 77% for HIV-positive and 87% for HIV-negative participants (AdjPR = 0.89, 95% CI 0.81-0.97, p = .01). Among HIV-positive participants, 41% had moderate neurocognitive impairment, 15% had severe neurocognitive impairment, and 44% were normal. For moderate neurocognitive impairment, the rate of ADL agreement was 69% and for severe neurocognitive impairment, it was 66%. Compared to non-impaired HIV-positive participants (86% ADL agreement), ADL agreement was lower with moderate impairment (AdjPR = 0.89, 95%CI 0.81-0.98, p = .023) and severe impairment (AdjPR = 0.77, 95%CI 0.63-0.95, p = .014). Gender, education and CD4 count were not associated with ADL agreement. HIV-positive persons with neurocognitive impairment have lower agreement with caregivers' reports of ADL than HIV-positive persons without cognitive impairment.
- Published
- 2019
- Full Text
- View/download PDF
41. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
- Author
-
Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Grant I, and Letendre SL
- Subjects
- Adult, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, HIV Infections cerebrospinal fluid, HIV Infections drug therapy, HIV Infections immunology, HIV-1 immunology, Humans, Longitudinal Studies, Male, Middle Aged, Odds Ratio, RNA, Viral, Treatment Outcome, Cerebrospinal Fluid virology, HIV Infections virology, HIV-1 genetics, Viral Load
- Abstract
Background: Few large projects have evaluated the factors that influence the HIV RNA concentrations (viral load) in cerebrospinal fluid (CSF) during antiretroviral therapy (ART) over time. We aimed to determine the correlates of HIV RNA in CSF in a large cohort., Methods: We analysed longitudinal data from adults living with HIV in the US CHARTER cohort. Participants in the CHARTER study were recruited from six US academic medical centres-in Baltimore (MD), Galveston (TX), New York (NY), St Louis (MO), San Diego (C92A), and Seattle (WA). Participants in this study had been assessed at least three times between Sept 4, 2003, and Sept 14, 2010, and were taking ART and underwent venous and lumbar puncture with measurement of HIV RNA concentration at all assessments. The lower limit of quantification of the HIV RNA assays was 50 copies per mL. Data were analysed with longitudinal mixed effects logistic regression to identify correlates of HIV RNA concentration (as a binary [detectable or not] and as a continuous variable) in CSF over time. We tested demographic characteristics, plasma HIV RNA, nadir and current CD4 cell count in blood, current CD8 cell count in blood, estimated duration of HIV infection, AIDS diagnosis, duration of ART, adherence to ART, ART characteristics, and CSF characteristics as potential correlates., Findings: At the time of analysis, 2207 assessments from 401 participants met the criteria for inclusion in this study. Mean duration of observation was 33·7 months (range 12-84). HIV RNA concentrations in 710 (32·2%) plasma specimens and in 255 (11·6%) CSF specimens were greater than the lower limit of quantification. The best multivariate model of HIV RNA concentration in CSF greater than the lower limit of quantification over time included increased plasma HIV RNA concentration (odds ratio 18·0 per 1 log
10 copy per mL, 95% CI 11·3 to 28·8; p<0·0001), increased CSF leucocyte count (2·01 per 5 cells per μL, 1·61 to 2·39; p<0·0001), decreased CD4 cell count (0·53 per 5 square-root cells per μL, 0·35 to 0·79; p=0·0025), decreased CNS penetration-effectiveness value (0·71 per unit, 0·56 to 0·92; p=0·0078), increased CD8 cell count (1·51 per 5 square-root cells, 1·11 to 2·06; p=0·0089), and protease inhibitor use (3·26, 1·04 to 10·23; p=0·039; model R2 =0·22, p<0·0001). Analyses of continuous HIV RNA concentration in CSF that accounted for censoring below the lower limit of quantification had similar findings, although increased HIV RNA concentrations in CSF were also associated with black ethnicity (change in log10 HIV RNA concentration in CSF 0·205, 0·0367 to 0·3733; p=0·017), increased total protein in CSF (0·0025, -0·0002 to 0·0052; p=0·069), and the presence of addictive-drug metabolites in urine (0·103, -0·013 to 0·219; p=0·081)., Interpretation: The identified correlates of HIV RNA concentration in CSF during ART could strengthen clinical prediction of risk for failure to achieve or maintain HIV RNA suppression in CSF. Because most participants in this analysis were ART-experienced and were taking a three-drug regimen that did not include an integrase inhibitor, future research should focus on participants who are taking their first ART regimens or regimens that include integrase inhibitors or two drugs., Funding: The work was supported by the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
42. Neuropsychological changes in efavirenz switch regimens.
- Author
-
Li Y, Wang Z, Cheng Y, Becker JT, Martin E, Levine A, Rubin LH, Sacktor N, Ragin A, and Ho K
- Subjects
- Adult, Alkynes, Anti-HIV Agents administration & dosage, Benzoxazines administration & dosage, Cohort Studies, Cyclopropanes, Female, Humans, Male, Middle Aged, Severity of Illness Index, Anti-HIV Agents adverse effects, Benzoxazines adverse effects, Depression pathology, Drug Substitution, HIV Infections drug therapy, Neuropsychological Tests
- Abstract
Background: Efavirenz is associated with side effects involving the central nervous system. However, it remains largely unknown whether switching off EFV improves neuropsychological performance., Methods: We utilized data from the Multicenter AIDS Cohort Study (MACS). Participants were categorized by their use of EFV: never on EFV (No EFV), continuously on EFV (No Switch-OFF) and on EFV and then switched off (Switch-OFF). Baseline time points were defined as visits when first neuropsychological data were available. In Analysis 1, we compared neuropsychological and Center for Epidemiological Studies-Depression Scale (CES-D) scores before and after EFV switch in Switch-OFF group, aligning participants at the time of switch. Analysis 2 evaluated trajectory of neuropsychological/CES-D score among the three groups., Results: This analysis included 1989 HIV-seropositive participants with neuropsychological data (1675 in No EFV, 44 in No Switch-OFF, and 270 in Switch-OFF group). At baseline, participants had a median age of 37 years, median CD4 cell count 442 cells/μl, and 22.9% viral suppression rate. In Analysis 1, neuropsychological and CES-D scores did not show clinically significant changes over 2 years prior to and 4 years after switch in Switch-OFF group. In Analysis 2, trends in neuropsychological and CES-D scores in the three different groups did not show significant differences during a median of 3.2 years of follow-up., Conclusion: Discontinuation of EFV is not associated with changes in neuropsychological performance or severity of depression in men. Furthermore, we did not observe differences among participants who were never on EFV, continuously on EFV, and on EFV and then switched off.
- Published
- 2019
- Full Text
- View/download PDF
43. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
- Author
-
Sacktor N, Saylor D, Nakigozi G, Nakasujja N, Robertson K, Grabowski MK, Kisakye A, Batte J, Mayanja R, Anok A, Gray RH, and Wawer MJ
- Subjects
- AIDS Dementia Complex drug therapy, Adult, Cohort Studies, Female, HIV Seropositivity drug therapy, HIV-1 drug effects, Humans, Male, Middle Aged, Multivariate Analysis, Rural Population, Uganda, Viral Load, Young Adult, Anti-Retroviral Agents therapeutic use, HIV Infections complications, HIV Infections drug therapy, Neurocognitive Disorders drug therapy
- Abstract
Background: Combination antiretroviral therapy (ART) improves HIV-associated neurocognitive disorder (HAND) stage in the United States where subtype B predominates, but the effect of ART and subtype on HAND stage in individuals in Uganda with subtypes D and A is largely unknown., Setting: A community-based cohort of participants residing in Rakai, Uganda., Methods: Three hundred ninety-nine initially ART-naive HIV-seropositive (HIV+) individuals were followed up over 2 years. Neurological and neuropsychological tests and functional assessments were used to determine HAND stage. Frequency and predictors of HAND and HIV-associated dementia (HAD) were assessed at baseline and at follow-up after ART initiation in 312 HIV+ individuals. HIV subtype was determined from gag and env sequences., Results: At 2-year follow-up, HAD frequency among HIV+ individuals on ART (n = 312) decreased from 13% to 5% (P < 0.001), but the overall frequency of HAND remained unchanged (56%-51%). Subtype D was associated with higher rates of impaired cognition (global deficit score ≥ 0.5) compared with HIV+ individuals with subtype A (55% vs. 24%) (P = 0.008). Factors associated with HAD at baseline were older age, depression, and plasma HIV viral load >100,000 copies/mL. At follow-up, age and depression remained significantly associated with HAD., Conclusions: HIV+ individuals on ART in rural Uganda had a significant decrease in the frequency of HAD, but HAND persists after 2 years on ART. The current guideline of immediate ART initiation after HIV diagnosis is likely to greatly reduce HAD in sub-Saharan Africa. Further studies of the effect of HIV subtype and neurocognitive performance are warranted.
- Published
- 2019
- Full Text
- View/download PDF
44. Vitamin D is not associated with HIV-associated neurocognitive disorder in Rakai, Uganda.
- Author
-
Saylor D, Nakigozi G, Pardo CA, Kisakye A, Kumar A, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, and Sacktor N
- Subjects
- Adult, Female, Humans, Male, Uganda, Vitamin D blood, Vitamin D cerebrospinal fluid, AIDS Dementia Complex blood, AIDS Dementia Complex cerebrospinal fluid, Vitamin D analogs & derivatives, Vitamin D-Binding Protein blood
- Abstract
We investigated whether vitamin D is associated with HIV-associated neurocognitive disorder (HAND). HIV-infected (HIV+) antiretroviral therapy (ART)-naïve adults in rural Uganda underwent a neurocognitive battery for determination of HAND stage at baseline and after 2 years. Baseline serum 25-hydroxyvitamin D (25OH-D) and serum and cerebrospinal fluids (CSF) vitamin D-binding protein (VDBP) were obtained. Of the 399 participants, 4% (n = 16) were vitamin D deficient (25OH-D < 20 ng/mL). There was no association between 25OH-D, serum or CSF VDBP, and HAND stage at baseline or follow-up. Future studies in a population with higher levels of vitamin D deficiency may be warranted.
- Published
- 2019
- Full Text
- View/download PDF
45. Effects of comorbidity burden and age on brain integrity in HIV.
- Author
-
Saloner R, Heaton RK, Campbell LM, Chen A, Franklin D Jr, Ellis RJ, Collier AC, Marra C, Clifford DB, Gelman B, Sacktor N, Morgello S, McCutchan JA, Letendre S, Grant I, and Fennema-Notestine C
- Subjects
- Adult, Brain diagnostic imaging, Cohort Studies, Comorbidity, Cross-Sectional Studies, Female, Gray Matter drug effects, Gray Matter pathology, HIV drug effects, Humans, Linear Models, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Middle Aged, Multivariate Analysis, Neuropsychological Tests, Sustained Virologic Response, White Matter drug effects, White Matter pathology, Aging, Anti-Retroviral Agents therapeutic use, Brain drug effects, Brain pathology, HIV Infections drug therapy, Neuroimaging
- Abstract
Objective: The influence of confounding neurocognitive comorbidities in people living with HIV (PLWH) on neuroimaging has not been systematically evaluated. We determined associations between comorbidity burden and brain integrity and examined the moderating effect of age on these relationships., Design: Observational, cross-sectional substudy of the CNS HIV Antiretroviral Therapy Effects Research cohort., Methods: A total of 288 PLWH (mean age = 44.2) underwent structural MRI and magnetic resonance spectroscopy as well as neurocognitive and neuromedical assessments. Consistent with Frascati criteria for HIV-associated neurocognitive disorders (HAND), neuromedical and neuropsychiatric comorbidity burden was classified as incidental (mild), contributing (moderate), or confounding (severe-exclusionary) to a diagnosis of HAND. Multiple regression modeling predicted neuroimaging outcomes as a function of comorbidity classification, age, and their interaction., Results: Comorbidity classifications were 176 incidental, 77 contributing, and 35 confounded; groups did not differ in HIV disease characteristics. Relative to incidental and contributing participants, confounded participants had less cortical gray matter and more abnormal white matter and ventricular cerebrospinal fluid, alongside more neuroinflammation (choline, myo-inositol) and less neuronal integrity (N-acetylaspartate). Older age exacerbated the impact of comorbidity burden: to a greater extent in the confounded group, older age was associated with more abnormal white matter (P = 0.017), less total white matter (P = 0.015), and less subcortical gray matter (P = 0.014)., Conclusion: Neuroimaging in PLWH reveals signatures associated with confounding neurocognitive conditions, emphasizing the importance of evaluating these among individuals with suspected HAND. Older age amplifies subcortical and white matter tissue injury, especially in PLWH with severe comorbidity burden, warranting increased attention to this population as it ages.
- Published
- 2019
- Full Text
- View/download PDF
46. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
- Author
-
Robertson KR, Jiang H, Kumwenda J, Supparatpinyo K, Marra CM, Berzins B, Hakim J, Sacktor N, Campbell TB, Schouten J, Mollan K, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firhnhaber C, Murphy R, Hall C, Marcus C, Naini L, Masih R, Hosseinipour MC, Mngqibisa R, Badal-Faesen S, Yosief S, Vecchio A, and Nair A
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Female, HIV Infections drug therapy, HIV Infections epidemiology, Humans, Internationality, Longitudinal Studies, Male, Neurocognitive Disorders classification, Neuropsychological Tests, Prevalence, Prospective Studies, Viral Load, HIV Infections complications, Health Resources, Neurocognitive Disorders epidemiology, Neurocognitive Disorders virology
- Abstract
Background: Neurocognitive impairment remains a common complication of human immunodeficiency virus (HIV) despite effective antiretroviral therapy (ART). We previously reported improved neurocognitive functioning with ART initiation in 7 resource-limited countries for HIV+ participants from the AIDS Clinical Trials Group (ACTG) 5199 International Neurological Study (INS). Here, we apply normative data from the International Neurocognitive Normative Study (INNS) to INS to provide previously unknown rates of neurocognitive impairment., Methods: The A5199 INS assessed neurocognitive and neurological performance within a randomized clinical trial with 3 arms containing World Health Organization first-line recommended ART regimens (ACTG 5175; PEARLS). The ACTG 5271 INNS collected normative comparison data on 2400 high-risk HIV-negative participants from 10 voluntary counseling and testing sites aligned with INS. Normative comparison data were used to create impairment ratings for HIV+ participants in INS; associations were estimated using generalized estimating equations., Results: Among 860 HIV+ adults enrolled in ACTG 5199, 55% had no neurocognitive impairment at baseline. Mild neurocognitive impairment was found in 25%, moderate in 17%, and severe in 3% of participants. With the initiation of ART, the estimated odds of impairment were reduced 12% (95% confidence interval, 9%, 14%) for every 24 weeks (P < .0001) on ART. Mild impairment dropped slightly and then remained at about 18% out to week 168., Conclusions: Almost half of HIV+ participants had neurocognitive impairment at baseline before ART, based on local norms. With ART initiation, there were significant overall reductions in neurocognitive impairment over time, especially in those with moderate and severe impairments., Clinical Trials Registration: NCT00096824., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
47. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.
- Author
-
Robertson KR, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell TB, Hakim J, Tripathy S, Hosseinipour MC, Marra CM, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, and Hall C
- Subjects
- Adult, Cognitive Dysfunction microbiology, Cognitive Dysfunction virology, Coinfection microbiology, Coinfection virology, Female, HIV-1, Humans, Internationality, Longitudinal Studies, Male, Motor Skills, Nervous System Diseases microbiology, Nervous System Diseases virology, Neuropsychological Tests, Prospective Studies, Quality of Life, Tuberculosis virology, Cognitive Dysfunction diagnosis, Coinfection complications, HIV Infections complications, Health Resources supply & distribution, Nervous System Diseases diagnosis, Tuberculosis complications
- Abstract
Background: AIDS Clinical Trial Group 5199 compared neurological and neuropsychological test performance of human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens. We investigated the impact of tuberculosis (TB) on neurological and neuropsychological outcomes., Methods: Standardized neurological and neuropsychological examinations were administered every 24 weeks. Generalized estimating equation models assessed the association between TB and neurological/neuropsychological performance., Results: Characteristics of the 860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/μL; and plasma HIV-1 RNA, 5.0 log copies/mL. At baseline, there were 36 cases of pulmonary, 9 cases of extrapulmonary, and 1 case of central nervous system (CNS) TB. Over the 192 weeks of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulmonary TB in 25 persons, and 3 observations of CNS TB in 2 persons. Prevalence of TB decreased with ART initiation and follow-up. Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01). TB was associated with diffuse CNS disease (P < .05). Furthermore, those with TB had 9.27 times (P < .001) higher odds of reporting decreased quality of life, and had 8.02 times (P = .0005) higher odds of loss of productivity., Conclusions: TB coinfection was associated with poorer neuropsychological functioning, particularly the fine motor skills, and had a substantial impact on functional ability and quality of life., Clinical Trials Registration: NCT00096824., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
48. Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates.
- Author
-
Saloner R, Campbell LM, Serrano V, Montoya JL, Pasipanodya E, Paolillo EW, Franklin D, Ellis RJ, Letendre SL, Collier AC, Clifford DB, Gelman BB, Marra CM, McCutchan JA, Morgello S, Sacktor N, Jeste DV, Grant I, Heaton RK, and Moore DJ
- Subjects
- Employment, Female, Humans, Male, Marijuana Use, Middle Aged, Activities of Daily Living, Cognition physiology, Cognitive Aging physiology, Cognitive Reserve physiology, HIV Infections physiopathology, Healthy Lifestyle physiology, Quality of Life
- Abstract
Objectives: Studies of neurocognitively elite older adults, termed SuperAgers, have identified clinical predictors and neurobiological indicators of resilience against age-related neurocognitive decline. Despite rising rates of older persons living with HIV (PLWH), SuperAging (SA) in PLWH remains undefined. We aimed to establish neuropsychological criteria for SA in PLWH and examined clinically relevant correlates of SA., Methods: 734 PLWH and 123 HIV-uninfected participants between 50 and 64 years of age underwent neuropsychological and neuromedical evaluations. SA was defined as demographically corrected (i.e., sex, race/ethnicity, education) global neurocognitive performance within normal range for 25-year-olds. Remaining participants were labeled cognitively normal (CN) or impaired (CI) based on actual age. Chi-square and analysis of variance tests examined HIV group differences on neurocognitive status and demographics. Within PLWH, neurocognitive status differences were tested on HIV disease characteristics, medical comorbidities, and everyday functioning. Multinomial logistic regression explored independent predictors of neurocognitive status., Results: Neurocognitive status rates and demographic characteristics differed between PLWH (SA=17%; CN=38%; CI=45%) and HIV-uninfected participants (SA=35%; CN=55%; CI=11%). In PLWH, neurocognitive groups were comparable on demographic and HIV disease characteristics. Younger age, higher verbal IQ, absence of diabetes, fewer depressive symptoms, and lifetime cannabis use disorder increased likelihood of SA. SA reported increased independence in everyday functioning, employment, and health-related quality of life than non-SA., Conclusions: Despite combined neurological risk of aging and HIV, youthful neurocognitive performance is possible for older PLWH. SA relates to improved real-world functioning and may be better explained by cognitive reserve and maintenance of cardiometabolic and mental health than HIV disease severity. Future research investigating biomarker and lifestyle (e.g., physical activity) correlates of SA may help identify modifiable neuroprotective factors against HIV-related neurobiological aging. (JINS, 2019, 25, 507-519).
- Published
- 2019
- Full Text
- View/download PDF
49. Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda.
- Author
-
Sohail S, Nakigozi G, Anok A, Batte J, Kisakye A, Mayanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Sacktor N, and Saylor D
- Subjects
- Adult, Cognitive Dysfunction complications, Cognitive Dysfunction epidemiology, Cognitive Dysfunction physiopathology, Cross-Sectional Studies, Depression complications, Depression epidemiology, Depression physiopathology, Female, HIV pathogenicity, HIV Infections complications, HIV Infections epidemiology, HIV Infections physiopathology, Headache complications, Headache epidemiology, Headache physiopathology, Humans, Middle Aged, Odds Ratio, Prevalence, Rural Population, Sex Factors, Surveys and Questionnaires, Uganda epidemiology, Cognitive Dysfunction diagnosis, Depression diagnosis, HIV Infections diagnosis, Headache diagnosis
- Abstract
Headache is common, but its prevalence and impact in sub-Saharan Africa and especially in HIV+ individuals is relatively unknown. We sought to determine the prevalence and functional impact of headache among HIV-infected (HIV+) adults in a cross-sectional observational cohort study in rural Rakai District, Uganda. Participants completed a sociodemographic survey, depression screen, functional status assessments, and answered the headache screening question, "Do you have headaches?" Participants responding affirmatively were assessed with the ID Migraine tool for diagnosis of migraine and Headache Impact Test-6 to determine functional impact of headache. Characteristics of participants with and without headaches and with and without functional impairment were compared using t tests for continuous variables, chi-square tests for categorical variables, and multivariate logistic regression. Of 333 participants, 51% were males, mean age was 37 (SD 9) years, 94% were on antiretroviral therapy (ART) and mean CD4 count was 403 (SD 198) cells/μL. Headache prevalence was 28%. Among those reporting headache, 19% met criteria for migraine, 55% reported functional impairment, and 37% reported substantial or severe impact of headache. In multivariate analyses, female sex (odds ratio (OR) 2.58) and depression (OR 2.49) were associated with increased odds and ART (OR 0.33) with decreased odds of headache. Participants with substantial/severe functional impact were more likely to meet criteria for depression (32% vs 9%). In conclusion, headache prevalence in HIV+ rural Ugandans was lower than global averages but still affected more than one quarter of participants and was associated with significant functional impairment.
- Published
- 2019
- Full Text
- View/download PDF
50. Screening for HIV-associated neurocognitive disorders in perinatally infected adolescents: youth-International HIV Dementia Scale validation.
- Author
-
Phillips NJ, Thomas KGF, Myer L, Sacktor N, Zar HJ, Stein DJ, and Hoare J
- Subjects
- AIDS Dementia Complex physiopathology, AIDS Dementia Complex therapy, Child, Cross-Sectional Studies, Evaluation Studies as Topic, Female, HIV Infections physiopathology, Humans, Infectious Disease Transmission, Vertical, Male, Neuropsychological Tests, Prevalence, South Africa epidemiology, AIDS Dementia Complex diagnosis, Anti-Retroviral Agents therapeutic use, HIV Infections complications, Health Services Needs and Demand, Mass Screening
- Abstract
Context: Perinatal HIV infection has adverse cognitive consequences into adolescence. However, there are no screening tools that assess risk for HIV-associated neurocognitive disorders in adolescent populations. Such screening tools are needed urgently for clinical care in resource-poor settings with a high prevalence of HIV., Objective: To investigate the performance of the International HIV Dementia Scale (IHDS) as a screening tool for HIV-associated neurocognitive disorders in perinatally adolescents., Design: The current study is a quantitative, quasiexperimental design., Methods: Perinatally HIV-infected adolescents aged 9-12 years were recruited from community health clinics into the Cape Town Adolescent Antiretroviral Cohort; matched HIV-negative controls from the same communities were enrolled. Each participant completed the IHDS and a comprehensive neuropsychological battery. The adult version of the IHDS was performed, except for two minor modifications. We evaluated the diagnostic validity of this modified instrument, the youth-IHDS (y-IHDS), using a four-step process that included sensitivity and specificity calculations, and generating receiver operating characteristic curves. Validity was measured against the youth HIV-associated diagnostic criteria., Results: At a cut-off score of 10 or less, the y-IHDS demonstrated good sensitivity (94%) but poor specificity (24%) for detecting all forms of neurocognitive disorders, with an acceptable area under the curve value of 0.695., Conclusion: The y-IHDS requires minimal resources and is based on a screening tool for adult HIV-associated cognitive disorders that is already widely used globally. Hence, this brief, cost-efficient, and valid screening tool may be a useful addition for clinicians working in resource-poor contexts in which adolescent HIV is highly prevalent.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.